Market Access

Collaboration aims to cut medication costs for patients with conditions ranging from high blood pressure to diabetes.

How drugmakers can navigate the program’s pricing challenges and regulatory developments.

Conditions require a disciplined approach to drug pricing.

Delays could harm older Americans, interest group states.

In what could presage a radical reshuffling of drug pricing and distribution, the insurer is dropping CVS Caremark as its PBM.

Illinois Governor JB Pritzker signed into a law a bill prohibiting PBM retaliation against pharmacists who disclose information during government proceedings.

Analysis requested by PhRMA indicates that these facilities charge anywhere from two to seven times what they originally paid.

Pharma Commerce team attends DIA's Annual Meeting for the first time.

A dive into the issue of evidence gaps, plus the case for a chief access officer.

While an option for financial assistance, patients should consider the challenges.

How the ‘fight-for-the-dollar’ is coming and likely will impact the bundled pricing of industry stakeholders.

As we approach the one-year anniversary of the IRA being signed into law, questions remain about how the new law will reverberate changes across the biopharma industry.

Medicare-eligible patients need to be enrolled in registry to get Medicare coverage for the anti-beta amyloid drug that is priced to cost $26,500 a year.

Micah Litow, Kalderos’ president and COO, discusses the importance of identifying and resolving noncompliant discount requests, along with addressing the gross-to-net gap for drug manufacturers.

Recent lawsuits are challenging the constitutionality of provisions in the Inflation Reduction Act.

Panel explores challenges that could affect their development.

Session offers a look into the Inflation Reduction Act’s impact on market conditions.

Session explores practicality of models for selling low-cost drugs.

Pharma company claims that the IRA’s drug pricing clauses violate the First and Fifth Amendments.

Indicates that reimbursement for new slate of Alzheimer’s treatments will occur only with the completion of studies to support full approval.

The latest on its implementation—and the implications for biopharma.

The Medicare Part D cap in 2025 won’t solve patients’ need for financial assistance.

New PC column explores commercialization trends and how pharma can adjust to the new squeeze of market, regulatory, pricing, and gross-to-net pressures.

How current frameworks influence coverage decisions and pricing negotiations.

The products, cloud revenue management solution provider says, are aimed at addressing supply chain challenges.